{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:27:41Z","timestamp":1791412061738,"version":"4.3.3"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","award":["EMA\/2018\/28\/PE"],"award-info":[{"award-number":["EMA\/2018\/28\/PE"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","award":["20_000177"],"award-info":[{"award-number":["20_000177"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2022.11.031","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T02:11:57Z","timestamp":1669083117000},"page":"251-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study"],"prefix":"10.1016","volume":"41","author":[{"given":"C","family":"Willame","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CE","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RJHJ","family":"Elbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Gini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Ehrenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kahlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Schink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Diez-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Mira-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JJ","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Vergara-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Giaquinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Stona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Huerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Mart\u00edn-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Garc\u00eda-Poza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"de Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Mart\u00ednez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Pallej\u00e0-Mill\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Arag\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JJ","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Souverein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NH","family":"Thurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Weibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"OH","family":"Klungel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MCJM","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2022.11.031_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/v12030254","article-title":"Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies","volume":"12","author":"Ahmed","year":"2020","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.vaccine.2022.11.031_b0010","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1016\/S2214-109X(21)00043-7","article-title":"An interactive website tracking COVID-19 vaccine development","volume":"9","author":"Shrotri","year":"2021","journal-title":"Lancet Glob Heal"},{"issue":"7","key":"10.1016\/j.vaccine.2022.11.031_b0015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","article-title":"A global database of COVID-19 vaccinations","volume":"5","author":"Mathieu","year":"2021","journal-title":"Nat Hum Behav"},{"issue":"23","key":"10.1016\/j.vaccine.2022.11.031_b0020","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2022.11.031_b0025","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.11.031_b0030","doi-asserted-by":"crossref","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 2021;384(22):2092\u2013101. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2104840.","DOI":"10.1056\/NEJMoa2104840"},{"issue":"24","key":"10.1016\/j.vaccine.2022.11.031_b0035","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.11.031_b0040","unstructured":"European Medicines Agency. EMA\u2019s safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events \u2013 further update [Internet]. 2021 [cited 2022 Feb 2]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/emas-safety-committee-continues-investigation-covid-19-vaccine-astrazeneca-thromboembolic-events."},{"key":"10.1016\/j.vaccine.2022.11.031_b0045","unstructured":"U.S. Food & Drug Administration. FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review [Internet]. 2021 [cited 2022 Feb 2]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough."},{"key":"10.1016\/j.vaccine.2022.11.031_b0050","unstructured":"Brighton Collaboration. Interim Case Definition of Thrombosis with Thrombocytopenia Syndrome (TTS) [Internet]. 2021 [cited 2022 Feb 2]. Available from: https:\/\/brightoncollaboration.us\/thrombosis-with-thrombocytopenia-syndrome-interim-case-definition\/."},{"key":"10.1016\/j.vaccine.2022.11.031_b0055","unstructured":"Brighton Collaboration. Myocarditis\/Pericarditis Case Definition [Internet]. 2021 [cited 2022 Feb 2]. Available from: https:\/\/brightoncollaboration.us\/myocarditis-case-definition-update\/."},{"key":"10.1016\/j.vaccine.2022.11.031_b0060","doi-asserted-by":"crossref","unstructured":"Vogel G, Couzin-Frankel J. Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. Science [Internet]. 2021 Jun 1 [cited 2022 Feb 2]; Available from: https:\/\/www.science.org\/content\/article\/israel-reports-link-between-rare-cases-heart-inflammation-and-covid-19-vaccination.","DOI":"10.1126\/science.abj7796"},{"key":"10.1016\/j.vaccine.2022.11.031_b0065","unstructured":"European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 June 2021 [Internet]. 2021 [cited 2022 Feb 2]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-june-2021."},{"key":"10.1016\/j.vaccine.2022.11.031_b0070","unstructured":"Centers for Disease Control and Prevention. ACIP Presentation Slides: July 22, 2021 Meeting [Internet]. 2021 [cited 2022 Feb 2]. Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2021-07-22.html."},{"key":"10.1016\/j.vaccine.2022.11.031_b0075","doi-asserted-by":"crossref","first-page":"B1","DOI":"10.1016\/j.vaccine.2019.07.081","article-title":"Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines","volume":"38","author":"Sturkenboom","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.11.031_b0080","unstructured":"European Medicines Agency. EMA commissions independent research to prepare for real-world monitoring of COVID-19 vaccines [Internet]. 2020 [cited 2022 Feb 2]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-commissions-independent-research-prepare-real-world-monitoring-covid-19-vaccines."},{"key":"10.1016\/j.vaccine.2022.11.031_b0085","unstructured":"European Network for Centres for Pharmacoepidemiology and Pharmacovigilance. Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines [Internet]. 2020 [cited 2022 Feb 2]. Available from: https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=37274."},{"key":"10.1016\/j.vaccine.2022.11.031_b0090","unstructured":"Brighton Collaboration. Priority List of Adverse Events of Special Interest: COVID-19 [Internet]. 2020 [cited 2022 Feb 2]. Available from: https:\/\/brightoncollaboration.us\/priority-list-aesi-covid\/."},{"key":"10.1016\/j.vaccine.2022.11.031_b0095","doi-asserted-by":"crossref","unstructured":"Thurin NH, Pajouheshnia R, Roberto G, et al. From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. Clin Pharmacol Ther 2022;111(1):321\u201331. Available from: https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/cpt.2476.","DOI":"10.1002\/cpt.2476"},{"key":"10.1016\/j.vaccine.2022.11.031_b0100","doi-asserted-by":"crossref","unstructured":"Gini R, Sturkenboom MCJ, Sultana J, Cave A, Landi A, Pacurariu A, et al. Different Strategies to Execute Multi-Database Studies for Medicines Surveillance in Real-World Setting: A Reflection on the European Model. Clin Pharmacol Ther 2020;108:228\u201335.","DOI":"10.1002\/cpt.1833"},{"issue":"8","key":"10.1016\/j.vaccine.2022.11.031_b0105","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/pds.4245","article-title":"CodeMapper: semiautomatic coding of case definitions. A contribution from the ADVANCE project","volume":"26","author":"Becker","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2022.11.031_b0110","unstructured":"Eurostat. Population change - Demographic balance and crude rates at national level [Internet]. 2021 [cited 2022 Feb 2]. Available from: https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/DEMO_GIND__custom_1110718\/bookmark\/table?lang=en&bookmarkId=39d70859-90b3-4d58-ba1e-5096d89d608d."},{"key":"10.1016\/j.vaccine.2022.11.031_b0115","article-title":"Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (2.0)","author":"Willame","year":"2021","journal-title":"Zenodo"},{"key":"10.1016\/j.vaccine.2022.11.031_b0120","unstructured":"VAC4EU. Dashboard Background rates of Adverse Events of Special Interest for COVID-19 vaccines [Internet]. 2021 [cited 2022 Feb 2]. Available from: https:\/\/vac4eu.org\/covid-19-tool\/."},{"key":"10.1016\/j.vaccine.2022.11.031_b0125","doi-asserted-by":"crossref","unstructured":"Gubernot D, Jazwa A, Niu M, et al. U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine 2021;39(28):3666\u201377. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X21005788.","DOI":"10.1016\/j.vaccine.2021.05.016"},{"key":"10.1016\/j.vaccine.2022.11.031_b0130","article-title":"Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: Multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2022.11.031_b0135","doi-asserted-by":"crossref","unstructured":"Huang D, Chan P-H, She H-L, et al. Secular trends and etiologies of venous thromboembolism in Chinese from 2004 to 2016. Thromb Res 2018;166:80\u20135. Available from: https:\/\/doi.org\/10.1016\/j.thromres.2018.04.021.","DOI":"10.1016\/j.thromres.2018.04.021"},{"key":"10.1016\/j.vaccine.2022.11.031_b0140","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study","volume":"373","author":"Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2022.11.031_b0145","unstructured":"Burn E, Li X, Kostka K, et al. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 20.6 million people in six European countries. medRxiv 2021;2021.05.12.21257083. Available from: http:\/\/medrxiv.org\/content\/early\/2021\/05\/13\/2021.05.12.21257083.abstract."},{"key":"10.1016\/j.vaccine.2022.11.031_b0150","doi-asserted-by":"crossref","unstructured":"Black S, Eskola J, Siegrist C-A, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009;374(9707):2115\u201322. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(09)61877-8.","DOI":"10.1016\/S0140-6736(09)61877-8"},{"key":"10.1016\/j.vaccine.2022.11.031_b0155","doi-asserted-by":"crossref","unstructured":"Black SB, Law B, Chen RT, Dekker CL, Sturkenboom M, Huang W-T, et al. The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety. Vaccine 2021;39(19):2712\u20138. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X2100284X.","DOI":"10.1016\/j.vaccine.2021.03.016"},{"key":"10.1016\/j.vaccine.2022.11.031_b0160","doi-asserted-by":"crossref","unstructured":"Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Vol. 25, Pharmacoepidemiol Drug Saf 2016;25:215\u201322.","DOI":"10.1002\/pds.3918"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22014293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22014293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:21:21Z","timestamp":1778505681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22014293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X22014293"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}